Search
Dibekacin
go.drugbank.com/drugs/DB13270ApprovedDibekacin is an aminoglycoside antibiotic marketed in Japan [L5623].
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Antibacterials for Systemic UseFluindione
go.drugbank.com/drugs/DB13136ApprovedWithdrawnFluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior. … Fluindione has been investigated for the treatment of Blood Coagulation Disorders.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexVarespladib methyl
go.drugbank.com/drugs/DB05737InvestigationalVarespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. … Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
Oveporexton
go.drugbank.com/drugs/DB21680Approved[L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … [L64069] Oveporexton has been recommended for scheduling as a controlled substance, and its final controlled-substance schedule and commercial availability are pending a determination by the Drug Enforcement
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalIt is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients.
INM005
go.drugbank.com/drugs/DB16499InvestigationalINM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). … Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235)
Categories: Experimental Unapproved Treatments for COVID-19Palivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalHumanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). … The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2).
Categories: Antiinfectives for Systemic UseProducts: Synagis 100mg/ml solution for Injection, SYNAGIS SOLUTION FOR INJECTION 100MG/MLPerflubron
go.drugbank.com/drugs/DB05791InvestigationalPerflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
Categories: Compounds used in a research, industrial, or household settingInfluenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16726ApprovedWithdrawnInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Categories: Inactivated Influenza A Virus VaccineSynonyms: Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15507ApprovedWithdrawnInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.